Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02190916 · ClinicalTrials.gov registry record

Vasculitis Illness Perception (VIP) Study

A clinical trial of Giant Cell Arteritis and Microscopic Polyangiitis, sponsored by University of South Florida.

Completed
Registry status
707
Enrollment target
1
Study location

NCT02190916 is a study of Giant Cell Arteritis and Microscopic Polyangiitis that has completed, run by University of South Florida. The registered enrollment target is 707 participants, below the 949-participant average among 7 other Giant Cell Arteritis trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02190916, a study of Giant Cell Arteritis and Microscopic Polyangiitis, has completed, sponsored by University of South Florida.

COMPLETED
Registry status
707 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to learn about how patients with vasculitis think about their illness and to assess to what extent patient perceptions of illness are associated with physical, mental, and social functioning

Study Locations (1)

Florida

  • University of South Florida Data Management Coordinating Center - Tampa

Trial Details

FieldValue
Enrollment Target 707 participants
Start Date 2011-10
Est. Completion 2013-10

Sponsor

University of South Florida

252 total trials

What the Registry Record Tells You About NCT02190916

The ClinicalTrials.gov registry entry for NCT02190916 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 707 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 949-participant average among 7 other Giant Cell Arteritis trials with a reported enrollment target (26% lower). The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.

The record links to 9 conditions, with Giant Cell Arteritis appearing as the primary indexed condition, and to 0 interventions.

NCT02190916 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT02190916 about?

NCT02190916 is a clinical study titled "Vasculitis Illness Perception (VIP) Study". The purpose of this study is to learn about how patients with vasculitis think about their illness and to assess to what extent patient perceptions of illness are associated with physical, mental, and social functioning

What is the current status of trial NCT02190916?

This trial is currently completed. The enrollment target is 707 participants. The study started on 2011-10. Estimated completion is 2013-10.

What conditions does trial NCT02190916 study?

This clinical trial studies the following conditions: Giant Cell Arteritis, Microscopic Polyangiitis, Takayasu's Arteritis, Polyarteritis Nodosa, Churg-Strauss Syndrome.

Who is sponsoring clinical trial NCT02190916?

This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02190916 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Giant Cell Arteritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.